- DiaSorin’s revenue for the second quarter was EU306 million, a 2% increase from the same period last year.
- The second quarter revenue closely met estimates of EU307.9 million.
- For the first half of the year, DiaSorin reported an EBIT of EU138 million.
- The company’s revenue for the first half totaled EU619 million, aligning with the estimate of EU620 million.
- DiaSorin’s EBITDA for the first half was EU204 million.
- The net income for the first half of the year was EU99 million.
- The stock has 8 buy ratings, 8 hold ratings, and 1 sell rating from analysts.
A look at DiaSorin SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, DiaSorin SpA, a company that manufactures reagents for in vitro diagnostics, is positioned for a positive long-term outlook. With a Growth score of 3 and Resilience score of 4, the company shows promising potential for expansion and a strong ability to withstand economic challenges. While its Value and Dividend scores both stand at 2, indicating average performance in these areas, DiaSorin SpA‘s Momentum score of 2 suggests a steady but not exceptional market momentum.
In summary, DiaSorin SpA is viewed favorably for its growth prospects and resilience in the face of uncertainties. Although the company’s value and dividend aspects are rated as moderate, its overall outlook is buoyed by a solid growth trajectory and a robust ability to navigate market volatility, possibly making it an attractive prospect for long-term investors seeking stability and potential growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
